# EDGAR Filing Document

**Accession Number:** 0001847345
**File Stem:** 0000000000-25-010426
**Filing Date:** 2025-9
**Character Count:** 2436
**Document Hash:** b00ce49655024a10887e543a54adf6be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010426.hdr.sgml**: 20260128

**ACCESSION NUMBER**: 0000000000-25-010426

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250924

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aspire Biopharma Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001847345
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-290359

**BUSINESS ADDRESS:**
- **STREET 1:** 23150 FASHION DRIVE, SUITE 232
- **CITY:** ESTERO
- **STATE:** FL
- **ZIP:** 33928
- **BUSINESS PHONE:** 561-704-8527

**MAIL ADDRESS:**
- **STREET 1:** 23150 FASHION DRIVE, SUITE 232
- **CITY:** ESTERO
- **STATE:** FL
- **ZIP:** 33928

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PowerUp Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210222

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PowsedrUp Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210222
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-25-014085

## Text-Extract

```

                                                           September 24, 2025

Kraig T. Higginson
Chairman, Chief Executive Officer
Aspire Biopharma Holdings, Inc.
23150 Fashion Drive, Suite 232
Estero, FL 33928

       Re: Aspire Biopharma Holdings, Inc.
           Registration Statement on Form S-1
           Filed September 18, 2025
           File No. 333-290359
Dear Kraig T. Higginson:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tim Buchmiller at 202-551-3635 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Arthur S. Marcus, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._